Adherium Appoints Digital Health Pioneer to Lead European Business Development

Digital health technology company, Adherium Limited, has appointed Scott Fleming as Senior Vice President of Business Development, Europe with immediate effect. - link here

Background

Adherium is a provider of digital health solutions to patients, pharmaceutical companies, healthcare providers and contract research organizations. Boasting the broadest range of “smart” medication sensors for respiratory medications globally, the company’s proprietary Smartinhaler™ platform has been independently proven to improve medication adherence and health outcomes for patients with chronic respiratory disease. .

The Smartinhaler™ platform has so far been used in more than 65 projects (clinical, device validation or other) and has been referenced in 56 peer reviewed journal articles. Clinical outcomes data has proven that the Smartinhaler™ platform can improve adherence by up to 59% in adults and 180% in children and reduce severe episodes by 60% in adults, leading to improved quality-of-life and demonstrating a substantial gain over current best practice treatment. The Company has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software, which allows it to sell these devices into international markets.

Replacing John Tarplee, who stepped down from the role at the end of December 2016, Scott Fleming is a founding member of the digital drug delivery movement. With 25 years’ sector experience covering strategy, device development, sales and marketing and big pharma, he brings valuable commercial knowledge and will continue to develop Adherium’s partnerships within the key European markets.

He will be based in Amsterdam, Netherlands, at Adherium’s European operational HQ and will continue to develop Adherium’s partnerships within the key European market and beyond.

Company comments

Garth Sutherland, CEO of Adherium said: “Bringing a pioneer of the digital health movement into our business is an exciting development as we continue to build our commercial capabilities, particularly in Europe. Scott’s 25 years’ experience in the field, combined with Adherium’s leading expertise will ensure a compelling proposition for partners and customers.”

Scott Fleming added: “Having first collaborated with Adherium nine years ago, working to enable data capture to the cloud, it is great to now be joining the team. I have watched Adherium’s technology grow to play a vital role providing key clinical data proofs for the digital drug delivery industry. I look forward to using my experience in this space to build on Adherium’s capabilities, reaching more patients and improving adherence and outcomes.”

Source: Globe Newswire